Gene Therapies for Ageing
Key Takeaways
- Gene therapies can introduce, silence, or edit genetic instructions, but ageing applications remain mostly experimental.
- Telomerase reverse transcriptase (TERT), follistatin, and Klotho are studied as mechanistic candidates in animal models and disease-focused translational research.
- Delivery vectors such as adeno-associated viruses (AAVs) and lentiviruses face payload, targeting, redosing, and immunogenicity limits.
- Genome-editing approaches may eventually support more precise interventions, but multiplex age-related applications remain early and speculative.
Why Gene Therapy Is Studied in Ageing Biology
Ageing is associated with processes such as macromolecular damage, telomere attrition, altered gene expression, and stem-cell dysfunction. Gene therapy is studied because it can change cellular instructions for longer periods than many small molecules. That does not mean the approach is proven for human ageing: durability, tissue targeting, reversibility, immune reactions, and long-term cancer risk remain central uncertainties.
Key Gene Therapy Targets
| Therapeutic Gene | Mechanism | Translational Progress and Results |
|---|---|---|
| Follistatin (FST) | Myostatin inhibitor. By blocking myostatin signalling, follistatin can increase muscle mass in some experimental contexts. | Supported by animal and disease-model research, including work relevant to muscle disorders. Evidence for general age-related use in humans is not established. |
| Telomerase (TERT) | Expresses the TERT enzyme, which helps maintain telomeres in some cellular contexts. | Mouse studies have reported delayed ageing phenotypes and longer lifespan after TERT gene delivery. Human relevance is uncertain, especially because telomerase biology intersects with cancer risk. |
| Klotho | Membrane-bound and circulating protein linked to phosphate metabolism, renal biology, insulin signalling, and neural function. | Overexpression has extended lifespan in some mouse models, but dosage, tissue specificity, and vector design remain unresolved for human translation. |
Vectors and Delivery Challenges
The vehicle carrying the genetic instruction is often the limiting factor for safety and efficacy.
- Adeno-associated viruses (AAVs): Commonly used for in vivo delivery because they can reach non-dividing cells and usually remain episomal. Their payload is small, tissue targeting is imperfect, and neutralizing antibodies can limit redosing.
- Cytomegalovirus-derived vectors: CMV-based systems are being explored because they may carry larger genetic payloads than AAVs. They remain less established for ageing applications and require careful safety evaluation.
The Gap Between Mice and Men
Positive findings in mice do not automatically translate to human ageing. Larger bodies require different dosing, tissue distribution is harder to control, and immune or liver toxicity can become dose-limiting. Telomerase is especially difficult to interpret because longer telomere maintenance may support tissue renewal in some settings while also intersecting with cancer biology. For these reasons, gene therapy for ageing should be read as an experimental research area rather than an available longevity intervention.
References
- Bernardes de Jesus, B. et al. "Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer." EMBO Molecular Medicine (2012). https://doi.org/10.1002/emmm.201200245
- David, A. E. et al. "Follistatin gene therapy improves muscle mass and strength in primate models." Molecular Therapy (2019). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390886/
This content is provided for academic reference only and does not constitute advice. Gene therapies for ageing are not approved as general anti-ageing or longevity interventions. The relevant evidence should be interpreted through the specific model, indication, vector, dose, and endpoint studied.